Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Down 53.5% in July

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) saw a large decrease in short interest during the month of July. As of July 31st, there was short interest totaling 3,860 shares, a decrease of 53.5% from the July 15th total of 8,310 shares. Based on an average daily volume of 25,979 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Kiora Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 14th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $10.00.

Kiora Pharmaceuticals Stock Performance

Shares of NASDAQ:KPRX traded down $0.04 on Friday, hitting $2.55. 41,172 shares of the company’s stock were exchanged, compared to its average volume of 18,071. Kiora Pharmaceuticals has a 1-year low of $1.76 and a 1-year high of $3.01. The company has a market capitalization of $11.28 million, a PE ratio of -1.02 and a beta of -0.38. The firm’s 50-day moving average is $2.56 and its 200 day moving average is $2.38.

Kiora Pharmaceuticals (NASDAQ:KPRX) last issued its earnings results on Friday, August 7th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.13.

Hedge Funds Weigh In On Kiora Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Investments LP acquired a new stake in Kiora Pharmaceuticals during the third quarter worth approximately $33,000. Citadel Advisors LLC acquired a new position in shares of Kiora Pharmaceuticals in the 3rd quarter valued at $125,000. Renaissance Technologies LLC boosted its holdings in shares of Kiora Pharmaceuticals by 71.0% in the 4th quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock valued at $42,000 after buying an additional 8,800 shares in the last quarter. DRW Securities LLC grew its position in shares of Kiora Pharmaceuticals by 199.2% in the 4th quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock valued at $217,000 after buying an additional 73,417 shares during the last quarter. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Kiora Pharmaceuticals in the 4th quarter valued at $152,000. 76.97% of the stock is currently owned by hedge funds and other institutional investors.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.